Re-Irradiation in Squamous Cell Carcinoma of the Head and Neck
, , , , , , and | Oct 11, 2023
About this article
Article Category: Research Article
Published Online: Oct 11, 2023
Page range: 40 - 48
Received: Dec 17, 2022
Accepted: Mar 01, 2023
DOI: https://doi.org/10.2478/fco-2023-0002
Keywords
© 2023 João Barros et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1:
Figure 2:
Stratification of overall survival (OS) groups at 2 years resulting from multivariate analysis (3).
| Class I | Treatment interval > 2 years, in patients submitted to surgery | 2 years OS of 62% |
| Class II | Treatment interval > 2 years, in patients not submitted to surgery or interval < 2 years, without organ dysfunction | 2 years OS of 40% |
| Class III | Interval between treatments < 2 years, with organ dysfunction | 2 years OS of 17% |
Toxicity grading differences between first and second irradiation.
| 59.0 (23) | 59.0 (23) | 21.0 (47) | |
| 33.3 (13) | 30.8 (12) | 31.0 (41) | |
| 7.7 (3) | 10.3 (4) | 24.5 (19) | |
| 35.9 (14) | 33.3 (13) | 20.0 (14) | |
| 17.9 (7) | 35.9 (14) | 26.0 (47) | |
| 33.3 (13) | 12.8 (5) | 39.0 (109) | |
| 12.8 (5) | 17.9 (7) | 24.0 (89) | |
| 23.1 (9) | 5.1 (2) | 34.0 | |
| 46.2 (18) | 76.9 (30) | 21.0 (36) | |
| 30.8 (12) | 17.9 (7) | 27.0 (92) | |
| 33.3 (13) | 20.5 (8) | 26.0 (117) | |
| 17.9 (7) | 35.9 (14) | 23.0 (46) | |
| 17.9 (7) | 15.4 (6) | 21.0 (25) | |
| 30.8 (12) | 28.2 (11) | 16.0 (35) | |
Univariate logistic regression of predictors for severe toxicity after first and second irradiations.
| 0.93 (0.11–7.82) | .949 | - | - | |
| 4.20 (0.33–53.1) | .268 | 0.24 (0.02–3.01) | .268 | |
| 0.70 (0.13–3.68) | .268 | 0.51 (0.10–2.59) | .416 | |
| 0.93 (0.11–7.82) | .949 | 0.48 (0.06–4.00) | .494 | |
| 5,08 (0,48–54,03) | .178 | 1.40 (0.35–5.54) | .632 | |
| - | - | 3.60 (0.32–40.23) | .298 | |
| 1.27 (0.74–2.17) | .383 | 0.97 (0.51–1.84) | .933 | |
| 0.98 (0.84–1.14) | .780 | 1.06 (0.98–1.13) | .134 | |
| 3.90 (0.96–15.82) | .057 | 1.25 (0.28–5.59) | .770 | |
Disease features at first and second radiotherapy irradiation.
| 30.8 (12) | ||
| 12.8 (5) | ||
| 10.3 (4) | ||
| 30.8 (12) | ||
| 12.8 (5) | ||
| 2.6 (1) | ||
| 89.7 (35) | 56.4 (22) | |
| 10.3 (4) | 33.3 (13) | |
| 0.0 (0) | 10.3 (4) | |
| 5.1 (2) | 20.5. (8) | |
| 33.3 (13) | 5.1 (2) | |
| 15.4 (6) | 23.1 (9) | |
| 17.9 (7) | 12.8 (5) | |
| 28.2 (11) | 38.5 (15) | |
| 41.0 (16) | 53.8 (21) | |
| 23.1 (9) | 15.4 (6) | |
| 28.2 (11) | 20.5 (8) | |
| 7.7 (3) | 10.3 (4) | |
| 100.0 (39) | 94.9 (37) | |
| 0.0 (0) | 5.1 (2) | |
| 20.5 (8) | 5.1 (2) | |
| 12.8 (5) | 15.4 (6) | |
| 15.4 (6) | 15.4 (6) | |
| 51.3 (20) | 64.1 (25) | |
| 2.0 (2) | 0.0 (0) | |
| 70.0 (4.0) | 60.0 (16) | |
| 56.4 (22) | 23.1 (9) | |
Concurrent chemotherapy (cCT) and toxicity grading following first and second irradiation.
| 50.0 (11) | 70.6 (12) | 44.4 (4) | 63.3 (19) | |
| 40.9 (9) | 23.5 (4) | 44.4 (4) | 26.7 (8) | |
| 9.1 (2) | 5.9 (1) | 11.1 (1) | 10.0 (3) | |
| 27.3 (6) | 47.1 (8) | 22.2 (2) | 36.7 (11) | |
| 18.2 (4) | 17.6 (3) | 33.3 (3) | 36.7 (11) | |
| 36.4 (8) | 29.4 (5) | 22.2 (2) | 10.0 (3) | |
| 18.2 (4) | 5.9 (1) | 22.2 (2) | 16.7 (5) | |
| 13.6 (3) | 35.3 (6) | 0.0 (0) | 6.7 (2) | |
| 50.0 (11) | 41.2 (7) | 77.8 (7) | 76.7 (23) | |
| 36.4 (8) | 23.5 (4) | 22.2 (2) | 16.7 (5) | |
| 22.2 (2) | 20.0 (6) | |||
| 33.3 (3) | 36.7 (11) | |||
| 22.2 (2) | 13.3 (4) | |||
| 22.2 (2) | 30.0 (9) | |||